Under the new international circumstances and integrated innovation betweenpharmaceutical industry and capital, in order to stimulate the vitality of the originaltechnology on pharmaceutical innovation in China, create a high-quality eco-systemfor pharmaceutical innovation, discuss the future of integrated innovation betweenpharmaceutical industry and capital, PhIRDA will host the 2022 CBlIC in SuzhouIndustrial Park on March 29-31, 2023.The 2022 CBllC will make further cooperation with government departments and well-known institutions around the world, and invite KOLs in pharmaceutical industry andeading experts to discuss policies and trends of global pharmaceutical innovationand financing to improve China's capability on transformation and innovation inpharmaceutical industry.
For more information, please check https://cbiic.phirda.com/
Registration: http://s.31url.cn/NaejvC8v
★Conference Opening Ceremony ★
Stage I: Speech by the organizer
Moderator.
Song Ruilin, Executive Chairman of China Pharmaceutical Innovation and Research Development Association
Welcome remarks by the host
Li Jia President of China Pharmaceutical Innovation and Research Development Association, Director of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and Director of State Key Laboratory of Drug Research
Ou Guansheng Chief Executive Officer of HKEx Group
Leadership of Suzhou Municipal Government
Stage II: Keynote Speech
Moderator:
Li Yan, President of China Pharmaceutical Innovation and Research Development Association 2021-2022, President of Qilu Pharmaceutical Group
Keynote report 1: Scientific regulation helps pharmaceutical power building
Reported by:
Leader of State Drug Administration
Keynote report 2: Future Trends of Anti-Infection Drugs
Rapporteur:
Jiang Jiandong Academician of Chinese Academy of Engineering, President of China Pharmaceutical Innovation and Research Development Association 2017-2918, President of Institute of Pharmaceutical Research, Chinese Academy of Medical Sciences
Keynote report 3: The Development Path of Pharmaceutical Innovation Industry under the
Macroeconomic Situation
Reported by:
Huatai Securities Research Institute
Stage III: Thematic discussion
Panel 1: The Road to China's Future Pharmaceutical Innovation
Discussants:
Chen Kaixian, Academician of Chinese Academy of Sciences, Deputy Chief Technical Engineer of Expert Group of the National Science and Technology Major Project "Major New Drug Creation”
Wang Yongjun, Honorary Chairman of the Professional Committee for Clinical Research on Brain and Neurological Drugs, China Pharmaceutical Innovation and Research Development Association, President and Deputy Secretary of the Party Committee of Beijing Tiantan Hospital, Capital Medical University
Hu Zhibin, Chairman of the Committee on Digitalization of Medicine and Innovative Therapeutics of China Pharmaceutical Innovation and Research Development Association, President and Deputy Secretary of the Party Committee of Nanjing Medical University
Wang Yaning, CEO of Lanlai Technology and former Director of FDA Quantitative Pharmacology Evaluation Office
Xu Xiaolin, Founding Partner and Chairman of Huagai Capital
Panel 2: New Path of Innovation and Development for Capital-Enabled Pharmaceutical Enterprises
Discussants:
Gu Ning Honorary Chairman of the Committee on Digitalization and Innovative Therapies of China Pharmaceutical Innovation and Research Development Association (Preparatory), Academician of the Chinese Academy of Sciences, Professor of Nanjing University
State Drug Administration Medical Device Technical Review Center leadership
Bao Haijie, Managing Director, Co-Head of Market Development, Hong Kong Stock Exchange
Liang Yingyu, C&E Chairman of Pharmaceutical Innovation Investment Committee of China Pharmaceutical Innovation and Research Development Association, Managing Partner of Qiming Venture Capital
Deng Jianmin, Senior Vice President Worldwide and General Manager, Greater China, Becton, Dickinson And Company
★Clinical Data World Premiere Session ★
Stage I
Moderator: Chen Li, CEO, Hualing Pharmaceutical Technology (Shanghai) Co.
Hualin Pharmaceutical Technology (Shanghai) Co.
Project 1: Dorzagliatin improves glucose-stimulated insulin secretion in early phase - an important factor in achieving blood glucose targets in diabetes
Rapporteur: Yang Wenying, Vice President of Asian Diabetes Association, Central Health Consultation Specialist
Wuhan Binhui Biotechnology Co.
Project 2: Recombinant human GM-CSF lysing herpes simplex virus type II (OH2) shows outstanding efficacy in the treatment of adult recurrent glioma
Rapporteur: Li Wenbin, Vice Chairman and Secretary General of the Special Committee on Clinical Research of Brain and Neurological Drugs, China Pharmaceutical Innovation and Research Development Association, Director of the Comprehensive Tumor Treatment Center, Beijing Tiantan Hospital, Capital Medical University
Wuhan Heyuan Biotechnology Co.
Project 3: Phase II clinical study of recombinant human serum protein of plant origin for the treatment of hypoalbuminemia in cirrhosis
Rapporteur: Niu Junqi, Director, Center for Infectious Diseases and Pathogen Biology, First Hospital of Jilin University
Stage II
Moderator: Wang Yinxiang, Vice Chairman of Pharmaceutical Research and development Committee of China Pharmaceutical Innovation and Research Development Association, Chairman and CEO of JACOBIO(HK)PHARMACEUTICALS CO.LIMITED
Shanghai Rongrui Pharmaceutical Technology Co.
Project 4: Phase I clinical study of lysing virus (OVV-01) injection for advanced solid tumors: preliminary results
Rapporteur: Lin Qiang, Secretary General of Anti-tumor Drug Clinical Research Committee of China Pharmaceutical Innovation and Research Development Association, Academic Leader of Oncology Department of North China Petroleum Administration General Hospital
Tennor Therapeutics (Suzhou) Co.
Project 5: Phase II clinical trial results of the multitargeted coupling molecule TNP-2092 for the treatment of cirrhotic hyperammonemia/hepatic encephalopathy
Rapporteur: Ma Zhenkun Founder and CEO of Tennor Therapeutics (Suzhou) Co.
Xi'an Xintong Institute of Pharmacy Co.,Ltd.
Project 6: Phase III clinical trial data of Paladofovir Mesylate
Rapporteur: Weili Jin Chief Medical Officer and Senior Vice President of Xi'an Xintong Institute of Pharmacy Co.,Ltd.
★Medical Digitalization Roadshow Special Session ★
Moderator: Zheng Can, Managing Director, Linear Venture
Project 1: Small molecule drug development based on protein dynamic changes
Rapporteur: Shen Qiancheng, CEO, Shanghai Nutshell Therapeutics Co.
Project 2: STEP platform to accelerate large molecule drug development using CADD/AI
Rapporteur: Jin Zhaoyu, Chairman and CEO of Mingji Biopharmaceuticals (Beijing) Co.
Project 3: Automation and intelligence drive drug discovery and innovation
Rapporteur: Zhang Peiyu, Chief Scientific Officer, Shenzhen XtalPi Technology Co.
Project 4: Leading platform for digital management and digital therapy of respiratory diseases in China
Rapporteur: Song Siyi General Manager of Wuxi Qiyi Medical Technology Co.
Project 5: Medical imaging based AI heart valve analysis and surgery planning system
Rapporteur: Yuan Jingxian, General Manager of Suzhou Peixin Technology Co.
Project 6: IBT InfiBrainTech - Digital Solution for Child and Adolescent Mental Health Services
Rapporteur: Sun Wei, Founder and Chairman of Beijing IBT Technology Co.
Project 7: Virtual Clinical Trial Strategy for High Performance Computing-based Cardiotoxicity Screening
Rapporteur: Song Zhen, Deputy Director of Enablement Institute, Network Intelligence Department, Pengcheng Laboratory
Project 8: Platform based on precision medicine and artificial intelligence technology empowerment
Rapporteur: Zhou Yan, Director of Strategic Cooperation, Hangzhou Repugene Technology Co., Ltd.
Project 9: Building a new generation of life science intelligence infrastructure tools
Rapporteur: Liu Jiapeng, General Manager of Shanghai X-IMAGING Information Technology Co.
★Special Session for Listed Companies ★
Moderator: Zhao Qun Partner of Suzhou Industrial Park Yuanhe Origin Venture Capital Management Co.
Project 1: Application of novel adjuvants in innovative vaccines
Rapporteur: Liu Yong Founder, Chairman of the Board and General Manager of Jiangsu Rec-Biotechnology Co., Ltd.
Project 2: Strong innovation and commercialization roots for value creation and sustainable development
Rapporteur: Su Weiguo, CEO and Chief Scientific Officer, Hutchison Pharmaceuticals (China) Co.
Project 3: Introduction to the new drug development pipeline and latest development progress of Ascletis Pharma (China) Co., Limited
Rapporteur: JINZI WU Founder, Chairman of the Board and Chief Executive Officer of Ascletis Pharma (China) Co., Limited
Project 4: 3SBio - a global leading integrated biopharmaceutical group
Rapporteur: Wang Fei, Chief Financial Officer, 3SBio Inc.
Project 5: Development of novel dual antibodies and dual anti-ADCs based on a fully human common light chain antibody platform (Ren-Lite)
Rapporteur: Guo Chaoshe, Vice General Manager of Biocytogen Pharmaceuticals (Beijing) Co., Ltd
Project 6: Shanghai Micurx Pharmaceutical Co., Ltd. - a committed player in the anti-infection field
Rapporteur: Li Zhile, Chief Financial Officer and Secretary of the Board, Shanghai Micurx Pharmaceutical Co., Ltd.
Project 7: High-quality concomitant diagnostics to facilitate precision drug development for tumors
Rapporteur: Liu Siqin, Senior Manager of Business Development, Xiamen Amoy Diagnostics Co.,Ltd.
Project 8: Application of parallel OX40 co-stimulation signaling platform in CAR-T development for hematological and solid tumors
Rapporteur: Yang Xuanming, Chief Scientist of Shanghai Longyao Biotechnology Co., Ltd. and Professor of Shanghai Jiaotong University
Moderator: Ji Xuwo, Founder & CEO of Precision Scientific
Project 9 : Development and industrialization of innovative anti-tumor nucleic acid interference drugs
Rapporteur: Yang Xianbin, CSO of Sirnaomics Ltd., China, General Manager of Suzhou Sirnaomics Ltd.
Project 10: Linking Global Innovation Resources to Serve Unmet Clinical Needs in China and Asia
Rapporteur: Wang Yizhe, Global CEO of Lianbio
Project 11: Betta Pharmaceuticals Co.Ltd: Focus on lung cancer targeted therapy, expand innovative drug development in oncology field
Rapporteur: Wu Lingxiang Secretary of the Board of Directors of Betta Pharmaceuticals Co.Ltd
Project 12: Development Strategy and Prospects of New Crown Drug FB2001
Rapporteur: Shao Qi, Senior Vice President and Chief Financial Officer, Frontier Bio-Pharmaceuticals (Nanjing) Co.
Project 13: Abbisko Therapeutics Co., Ltd. - Dedicated to the innovative and independent development of small molecule oncology drugs to address the unmet clinical needs of patients in China and around the world
Rapporteur: Zhang Zidong, Chief Financial Officer, Shanghai Abbisko Therapeutics Co., Ltd.
Project 14: Hengrui Pharma - Focus on innovation to build a multinational pharmaceutical group
Rapporteur:Tian Fei, Securities Representative, Jiangsu Hengrui Pharmaceutical Co.
Project 15: Boan Bio ---- A fully integrated biopharmaceutical company covering the entire industrial value chain
Rapporteur: Dou Changlin, President and COO of Shandong Boan Biotechnology Co., Ltd.
Project 16: Innovation-driving, technology-enabling ---- helps global innovative drug development
Rapporteur: Jianhua Cai, Group Senior Vice President, Viva Biotech Holdings
★Special Session for Non-listed Companies ★
Project 1: The world's only IND-approved autologous CD7-CAR-T cell drug for refractory relapsed T-ALL/LBL
Rapporteur: Yang Lin, Founder, Chairman and Chief Scientific Officer of PersonGen Pharmaceutical Technology (Suzhou) Co.
Project 2: Global clinical trial report of ACT001, an immunomodulatory agent in the brain
Rapporteur: Chen Yue, CEO of Tianjin Accendatech Pharmaceutical Technology Co.
Project 3 : Clinical value-oriented, make good medicine for better life
Rapporteur: Hei Yongjiang, Co-CEO of Umoja Biopharma Co.
Project 4 : Development of IN10018, the world's first new anti-tumor drug, the FAK inhibitor
Rapporteur: Cao Fei Chief Operating Officer of InxMed (Hong Kong) Limited
Project 5: Focus, Breakthrough, Lead - The Innovation Road of Qilu Pharmaceutical
Rapporteur: Zhu Yidong, Executive Vice President, Innovative Drug Research Institute, Qilu Pharmaceutical Co.
Project 6: FosunKite and China's first cell therapy drug Axicabtagene Ciloleucel Injection’s China real world data phase report and research directions and new developments in each clinical study
Rapporteur: Zhao Jinghua, Chief Medical Officer, Fosun Kite Biotechnology Co.
Project 7: RareStone Group - Building China's Rare Disease 2.0 Business Model
Rapporteur: Wang Hanbo, Head of Business Development and Innovation, Shanghai RareStone Health Technology (Group) Co.
Project 8: Jiayue Pharma - Innovation for Clinical Value
Rapporteur: Li Yongguo, Chairman and Chief Scientific Officer, Guangzhou Jiayue Pharmaceutical Technology Co.
Project 9: GEN HOUSE Pharmaceuticals - Breakthrough of non-druggable targets, focus on original innovation
Rapporteur: Kui-Feng Wang Founder & CEO of GEN HOUSE Pharmaceutical (Suzhou) Co.
Project 10: Research on Tyninad tablets for hyperuricemia and gout treatment
Rapporteur: Huang Changjiang, General Manager, Tianjin Pharmaceutical Research Institute Co.
Project 11: Third-generation lgE antibodies and other innovative drugs developed on Longbio's technology platform
Rapporteur: Liu Heng, General Manager of LongBio Biopharmaceutical (Suzhou) Co.
Project 12: Breakthrough technology platform for lysovirus vaccine-driven immune combination therapy for tumors
Rapporteur: Zhou Guoqing, Executive President of Shanghai Joint Biosciences Ltd.
Project 13: Application of QTsome, an efficient delivery system, in nucleic acid drug development
Rapporteur: Yang Yongsheng, Senior Vice President of Zhejiang Haichang Bio-tech Co. and Director of Nucleic Acid Innovation Institute
Project 14: Pioneer in the development of new drugs based on the insertion of fixed-point couplings of unnatural amino acids
Rapporteur: Xia Gang, Chief Scientific Officer, Zhejiang Xinma Biomedical Co.
Project 15: Hongyun Huaning (Hangzhou) Biomedical: Cracking the World Puzzle of GPCR Antibody New Drug Development
Rapporteur: Fang Xiansheng, Chief Financial Officer, Hongyun Huaning (Hangzhou) Biomedical Co., Ltd.
Project 16: Orbitalazine Fumarate Enteric Erythromycin Delayed-Release Capsules (SM-1) Project Introduction
Rapporteur: Jiang Yanlin, Chief Medical Officer, Shenzhen Zhenxing Pharmaceutical Technology Co.
Project 17: Development of Drugs for Gout and Other Innovative Drugs with Global Commercial Value
Rapporteur: Jin Wenqing, Executive Vice President, Jiangsu New Element Pharmaceutical Technology Co.
Project 18: New ideas for the development of small molecule drugs for the central nervous system
Rapporteur: Ma Weiwei, General Manager of Beijing JoeKai Biotech Co.
Project 19: NK cell immunotherapy drug development and industrialization
Rapporteur: Dai Zhaohui, General Manager & COO of Shanghai HYAMAB Biotechnology Co.
Project 20: BH-RACE novel nucleic acid drug platform
Rapporteur: Wang Hanming, Vice President, Wuhan Binhui Biotechnology Co.
Project 21: Nanjing Neurodawn Pharmaceutical Co., Ltd.--Leader in R&D of innovative drugs in the field of central nervous system
Rapporteur: Xia Yang Yu, Vice President of Investment, Nanjing Neurodawn Pharmaceutical Co., Ltd.
Project 22: Focusing on unmet clinical needs in digestion and metabolism, developing new multifunctional original drugs in parallel worldwide
Rapporteur: Yu Meng, Vice General Manager, China, Shenzhen HighTide Biopharmaceutical Ltd.
Project 23: Epiv-otide, an original broad-spectrum anti-inflammatory drug
Rapporteur: Xia Xianmin Chairman of Wuhan Yicheng Biotechnology Co.
Project 24: JS InnoPharm (Shanghai) Limited: Next Generation Tumor Precision Therapy
Rapporteur:Jintao Zhang, Executive Chairman of JS InnoPharm (Shanghai) Limited
Project 25: Full speed ahead for enterprise construction to boost gene and cell therapy industry
Rapporteur: He Yingke, CEO of Forecyte Bio(Shanghai) Limited
Project 26: Jian Xin Yuan Li Advanced Therapeutics Drug CDMO Platform
Rapporteur: Li Yuling CEO of Zhejiang Jian Xin Yuan Li Pharmaceuticals Co., Ltd.
Project 27: A reliable strategic partner for the integration of Chinese biomedical innovation into globalization
Rapporteur:Liu Yi Chief Medical Officer of DMED Bio (China)
Project 28: Recombinant high potency compound interferon for prevention or interruption of neocoronavirus contact infection and prevention of aggregated outbreaks
Rapporteur: Tang Junjun, Vice General Manager, Sichuan Huiyang Life Engineering Co.
Project 29: Roadshow of Bica Biotechnology (Guangzhou) Co., Ltd., a leading global pharmaceutical innovation company
Rapporteur: Dong Xiangyu, Vice President of R&D, Bica Biotechnology (Guangzhou) Co., Ltd.
Project 30: Innovative ADC Drug Development Based on Enzymatic Smart Continuous Coupling Process
Rapporteur: Qin Gang Chairman and Founder of Qide Medical Technology (Suzhou) Co.
Project 31: Clinical research progress of universal DNT cells for hematologic tumors
Rapporteur: Yang Liming, Chairman & CTO of Guangdong Ruisun Biotechnology Co.
Project 32: Gloria Bio Creating Miracle
Rapporteur: Sui Donghu, Vice President of Corporate Strategy, Guangzhou Gloria Biotechnology Co.
Project 33: Efficacy and safety of the combination of PD-L1 monoclonal antibody TQB2450 and anlotinib hydrochloride in the treatment of solid tumors
Unit name: Chia Tai Tianqing Pharmaceutical Group Co.
Rapporteur: Shi Meiqi, Chief Physician/Professor, Jiangsu Cancer Hospital
★Early stage project roadshow special session ★
Moderator: Yao Jun, Associate Professor, Academy of Life Sciences, Tsinghua University
Project 1 : Novel PROTAC drug APL-16-5
Rapporteur: Cen Shan, Researcher, Institute of Pharmaceutical Biotechnology, Chinese Academy of Medical Sciences
Project 2 : Innovative liver-specific targeted biologics for NASH
Rapporteur: Wang Qinghua, Chairman and General Manager of Shanghai INNOGEN Pharmaceutical Technology Co.
Project 3: Novel base-editing technology fills a gap in medical needs for the benefit of patients worldwide
Rapporteur: Mou Xiaodun, CEO of CORRECTSEQ (Shanghai) Biotechnology Co.
Project 4: AnDiCon Bio: a pioneer & leader in the field of anti-respiratory infection in China
Rapporteur: Zhu Xiaoyun, CEO of Jiaxing AnDiCon Biotechnology Co.
Project 5 : Novel Autoimmune Drug: MDI-1228
Rapporteur: Lu Liang, Chief Scientific Officer of Henan Medinno Pharmaceutical Technology Co., Ltd.
Project 6 : Preclinical study of an efficient and safe HPK1 inhibitor (ABM-2752)
Rapporteur: Chen Chen, Founder, Chairman and CEO of ABM Therapeutics (Shanghai) Technology Co.
Project 7: Ying Hui Pharmaceuticals - A leader in the development of new drugs based on stereo attack for lysing viruses
Rapporteur: Huang Yinghui Founder of Suzhou Yinghui Pharmaceutical Technology Co.
Project 8: Design ideas and clinical data for the world's first tumor-targeted IL-15
Rapporteur: Zhang Haizhou, Chief Executive Officer of BJ Bioscience (Hangzhou) Co.
Moderator: Peng Qing, Vice President of Investment, Northern Light Venture Capital
Project 9: CMBT - Marine small molecule drug candidates with whitening and anti-tumor functions
Rapporteur: Wang Xinwen, General Manager of Shenzhen Huahong Marine Biomedical Co.
Project 10: Disruptive protein-based in vivo in situ tissue reprogramming technology for malignant solid tumors
Rapporteur: Li Wenbao CEO of Suzhou Fuent Regenerative Medicine Ltd., Co.
Project 11: Anti-AD drug development technology and varieties
Rapporteur: Liu Rui, Professor, Institute of Pharmaceutical Biotechnology, Chinese Academy of Medical Sciences
Project 12: Establishment of a bRo5-based PROTAC drug-forming technology platform and discovery of novel BTK-targeted PCC degradation molecules
Rapporteur: Zhou Xinglu, CEO of Hangzhou Hezheng Pharmaceutical Co.
Project 13: Neutrophil Drugs for Solid Tumors
Rapporteur: Zhang Can, Professor, China Pharmaceutical University
Project 14: Innovative discovery of world-class small molecule drugs for respiratory diseases
Rapporteur: Zhu Jiawang, President of Suzhou INTRAGRAND PHARMA Co.
Project 15: Results of a U.S. clinical phase trial of First-in-class variant of collagenase RJV001 for topical lipolysis
Rapporteur: Shi Sheng, Vice General Manager, Hangzhou Rejuven Dermaceutical Co., Ltd.
Project 16: TAV0412: A novel multispecific antibody for treatment-refractory cancers
Rapporteur: Han Chao, Vice President of Research and Development, Tavotek Biotechnology (Jiangsu) Co.
★Medical device roadshow session★
Moderator: Zheng Wei, Assistant Director & Chief Medical Officer of Guolian Securities Research Institute
Project 1 : Molecular diagnostic products based on ultra-multiplex PCR technology
Rapporteur: Mao Lin, Chairman of Nanjing Puji Biological Co.
Project 2 : Tumor Tissue Origin Gene Testing - mRNA+Al for Cancer Precision Medicine
Rapporteur: Xu Qinghua, General Manager of Hangzhou Canhelp Genomics Co.,Ltd
Project 3: The first boron neutron capture cancer treatment in China
Rapporteur: Liu Junyang Chief Scientist, Peng Bo Holdings Limited (British Virgin Islands)
Project 4 : Home Hemodialysis (HD)
Rapporteur: Li Xianghai, Founder and General Manager, Shanghai Xinguang Biomedical Co.
Project 5: Full set of molecular diagnostic solutions provider --- all the underlying core modules are self-developed
Rapporteur: Zhu Kun, Chairman and General Manager of Beijing Origingene-tech Biotechnology co. LTD
Project 6: Home medical device based on targeted neuromodulation technology
Rapporteur: Ji Hualei, Chairman of Ningbo WAT Medical Technology Co.
Project 7 : Building a new generation of neurosurgical medical device platform
Rapporteur: Liu Yansang, President of Shenzhen PrimaNova Medical Technology Co.
Project 8: Development of a new bioactive bone material, Guxinsheng
Rapporteur: Song Yan, Founder and General Manager of Guxinsheng Biotechnology Co.
★International Project Cloud Roadshow Special Session★
Project 1 : Innovative therapy for biofilm infection
Rapporteur: Karim Lalji CEO of Microbion Corporation
Project 2: Innovative Therapeutic Development through Protein Modulation
Rapporteur: Max S. Cynader CEO and Co-Founder of Primary Peptides Inc.
Project 3 : mRNA 2.0: Development of durable mRNA-based hybrid antitumor therapeutics
Rapporteur: Rajiv Datar Co-Founder & CEO of Propelle Therapeutics Inc.
Project 4 : WE Medicine: Harnessing the natural dynamics of systems biology drugs to extend life
Rapporteur: Peikwen Cheng Co-Founder & CEO of Yiviva
Project 5 : SLC0111 - A first-in-class clinical-stage small molecule CAIX inhibitor for cancer therapy
Rapporteur: Zhang Zaihui, Co-founder, Chief Scientist, Vice President of Research and Development, New SignalChem Life Sciences
Project 6 : ViroginBiotech: A global leader in lysovirus therapy
Rapporteur: Zhao Huan Yu, Vice President of BD, ViroginBiotechCo.,Ltd
★Policy Sharing Forum★
Moderator: Feng Lan, Secretary General, China Pharmaceutical Innovation and Research Development Association
Report 1: Continuous improvement of drug regulatory standards to promote high-quality development of China's pharmaceutical innovation
Rapporteur: Leadership of Center of Drug Evaluation, State Drug Administration (by invitation)
Report 2 : Sound cell therapy regulatory policies to promote industrial innovation and development
Rapporteur: Shi Lan, Director of Drug Administration, Shanghai Municipal Drug Administration
Report 3: Deepening Health Insurance Policy Reform to Empower Sustainable Innovation in Medicine
Rapporteur: Xuan Jianwei, Deputy Director, Pharmaceutical Policy Committee, China Pharmaceutical Innovation and Research Development Association, Director, Institute of Pharmaceutical Economics, School of Pharmacy, Sun Yat-sen University
Report 4 : Synergistic development of pharmacovigilance reform and industrial innovation from the perspective of capital (prepared)
Rapporteur: He Juying Member of the Special Committee on Pharmaceutical Policy of China Pharmaceutical Innovation and Research Development Association, Chief Pharmaceutical Analyst of CITIC Capital Securities (by invitation)
Topic Discussion: Change and Transformation - High Quality and Sustainability in Pharmaceutical Innovation
l l Trends and Challenges of Drug Regulatory Reform Leading to High Quality Development
l l Enhancing the “Medical Insurance, Hospital and Drug Industry Co-development” to Raise the Level of Pharmaceutical Innovation
l l Health Insurance Payment System Reform and Sustainable Pharmaceutical Innovation
l l Current Situation and Future Trends of Investment and Financing in Innovative Drug Market
Moderator: Xuan Jianwei, Deputy Director, Pharmaceutical Policy Committee, China Pharmaceutical Innovation and Research Development Association, Director, Institute of Pharmaceutical Economics, School of Pharmacy, Sun Yat-sen University
Discussantsss: CDE Leaders of State Drug Administration
Shi Lan, Director of Drug Regulatory Department, Shanghai Municipal Drug Administration
Xuan Jianwei, Deputy Director, Pharmaceutical Policy Committee, China Pharmaceutical Innovation and Research Development Association, Director, Institute of Pharmaceutical Economics, School of Pharmacy, Sun Yat-sen University
He Juying Member of the Special Committee on Pharmaceutical Policy of China Pharmaceutical Innovation and Research Development Association, Chief Pharmaceutical Analyst of CITIC Capital Securities (by invitation)
Li Yiping Co-founder, Chairman and CEO of Shanghai Juno Biotechnology Co.
Cui Yiling Senior Vice President, Hmplglobal Pharmaceuticals (Shanghai) Co.
★Forum on Rare Diseases and Pediatric Drug Use★
Opening speech: Li Linkang, Executive Director of China Rare Disease Alliance
Report 1: Review Evidence Considerations for Drugs for Rare Diseases and Pediatric Drugs
Rapporteur: State Drug Administration Drug Review Center (by invitation)
Report 2: Access to medicines for patients with rare diseases vs. unmet clinical need
Rapporteur: Shao Rong, Professor, China Pharmaceutical University, Executive Director, Institute of Drug Regulatory Science, China Pharmaceutical University
Report 3: Children's clinical drug use dilemma and the way to break it
Rapporteur: Wang Xiaoling, Director, Department of Pharmacy, Beijing Children's Hospital, Capital Medical University
Report 4: Clinical Development of Rare Disease Drugs in China with a Global Perspective
Rapporteur: Ping Li, Senior Vice President of Clinical Development and Operations, CANbridgepharma Limited
Report 5: Patient-Centered Drug Development and Pipeline Building for Rare Diseases
Rapporteur: Xiang Yu, CEO of RareStone Group
Topic Discussion: Thinking about strengthening unmet demand for drug development and building a system for drug use assurance
Moderator: Liu Junsai Member of the National Expert Committee on Rare Disease Treatment and Protection, Deputy Director of the Special Committee on Pharmaceutical Policy of China Pharmaceutical Innovation and Research Development Association
Discussants: Shao Rong, Professor of China Pharmaceutical University and Executive Director of the Institute of Drug Regulatory Science of China Pharmaceutical University
Wang Xiaoling, Director, Department of Pharmacy, Beijing Children's Hospital, Capital Medical University
Li Ping, Senior Vice President of Clinical Development and Operations, CANbridgepharma Limited
Xiang Yu, CEO of RareStone Group
Guo Qin, Head of Rare Disease Area, AstraZeneca China R&D Center
★Science and Technology Innovation Board Forum★
Moderator: Li Pengju, Assistant to President and General Manager of Medical and Health Care Division of Eagle Investment Holdings
Keynote Report 1: Introduction to the System and Current Operation of the Science and Technology Innovation Board
Rapporteur: Wang Jia, Head of Jiangsu-Anhui Group, Market Development Department, Shanghai Stock Exchange
Keynote Report 2: Investment thinking in the pharmaceutical and medical device sectors in the new economic cycle
Rapporteur: Xiao Zhi, Co-Head and Managing Director of the Life Sciences team of SDIC Innovation Investment
Keynote Report 3: New Trends of Science and Technology Board Listing for Large Health Enterprises under the New Normal of Market Volatility
Rapporteur: Liao Yixing, Co-Head of Investment Banking, Health Industry Department, Huatai United Securities
Keynote Report 4: Biopharmaceutical Companies' Science and Technology Board Listing: New Trends and Strategies in 2022
Rapporteur: Li Chenliang, Partner, Head of Capital Markets, Shanghai Office, Jun He Law Office
Topic Discussion: Science and Technology Innovation Board Helps Innovation Development of Pharmaceutical Industry
Moderator: Liao Yixing, Co-Head of Investment Banking, Health Industry Department, Huatai United Securities
Discussants: Wang Jia, Wang Jia, Head of Jiangsu-Anhui Group, Market Development Department, Shanghai Stock Exchange
Xiao Zhi, Co-Head and Managing Director of the Life Sciences team of SDIC Innovation Investment
Wu Nan, Chief Financial Officer and Secretary of the Board of Directors of Beijing Infervision Technology Co. Ltd.
Huang Xiaoli, partner of Jun He Law Firm
★Investor Experience Sharing ★
Moderator: Chen Kan, Partner, Qiming Venture Partners
Keynote Report 1: (Title to be determined)
Rapporteur: Liang Yingyu, Managing Partner, Qiming Venture Partners
Keynote 2: Taking the pulse of the changing times and charting the way to healthcare
Rapporteur: Li Xi, President, Medical, Health, Culture and Tourism Finance Division, Ping An Bank
Keynote 3: Innovation and Investment in Biopharmaceuticals in the Post-Epidemic Era
Rapporteur: Zhu Jinqiao, Founder and Chairman of EFUNG CAPITAL
Keynote Report 4: Investment value and opportunities in the field of big health
Rapporteur: Luo Fei, Founding Partner of Green Pine Capital Partners
Discussion 1: Today and Tomorrow of China PE Healthcare M&A Deals
Moderator: Chen Zhixing, Managing Director of Centurium Capital
Discussants: Wan Jiahui, Managing Director of CITIC Capital
Tang Ke, Managing Director of CPE
Shi Long, Managing Director of Warburg Pincus
Tao Xudong, Partner-in-Charge of the Medical Practice Group of Junhe Law Firm
Discussion 2: Opportunities and challenges for pharmaceutical investment in the new situation
Moderator: Chen Kan, Partner, Qiming Venture Partners
Discussants: Liang Lin, Partner, Lilly Asia Ventures
Yi Lin, Partner of GL Capital
Lu Hai, Managing Director of China Life Private Equity Investment Company Limited
Xu Xiaoou, Managing Director and Head of Healthcare Investments, Greater China, Asset Management, Goldman Sachs (Asia) LLC
★Pharmaceutical Digitalization Forum★
Moderator: Sun Zhe, Secretary General of Committee on Digitalization of Medicine and Innovative Therapies of China Pharmaceutical Innovation and Research Development Association
Leadership Message
Keynote Report 1: Do a good job in technical review, serving digital medical device industry development
Rapporteur: Guo Zhaogun, Director of Review Department II, Instrumentation Review Center, State Drug Administration
Keynote Report 2: Combining online and offline for broad empowerment, building a new ecology of health and recreation
Rapporteur: Hu Jianzhong, Deputy Secretary of the Party Committee, Xiangya Hospital, Central South University
Keynote Report 3: Deconstructing Molecular Phenotypes, Exploring Quality of Life
Rapporteur: Cheng Xiaoliang, Chairman of Jiangsu QLife Medical Technology Group Co.
Keynote Report 4: Artificial Intelligence Helps Build a Community of Human Health Destiny
Rapporteur: Chen Kuan, Founder and Chairman of Infervision Medical
Keynote Report 5: New Tools and Processes for New Paradigm-Driven Drug Design in Al for Science
Rapporteur: Sun Weijie, Founder and Chief Executive Officer of Beijing DEEPCG Technology Co.
Keynote Discussion: Opening a New Chapter in Healthcare Digitalization
Moderator: Bao Haijie, Managing Director, Co-Head of Market Development, HKEx
Discussants: He Qi, Co-founder and CEO of TandemAI Medical Technology Co.
Yin Pengcheng, Partner of Eight Roads Capital
Xu Lili, Chief Financial Officer of ClouDr Group HK Limited
★International Forum on Innovative Drug Regulation★
Keynote Presentation 1: "What to think" about new drug development under clinical value guidelines
Rapporteur: Xiao Shen, Chief Strategy Officer, 3D Medicines
Keynote Presentation 2: The Impact of FDA 0ptimus and Equity Programs on Global New Cancer Drug Development
Rapporteur: Wang Yaning, CEO of Wuhan Createrna Science and Technology
Keynote Presentation 3: Management of CMC Clinical-to-Market Changes - Quality to Quantity Conversion
Rapporteur: Liu Juhong, President of Global Submission LLC.
Keynote Presentation 4: Exploring Clinical Trial Strategies of Innovative Pharmaceutical Companies for Dual Reporting in China and the U.S.
Rapporteur: Ding Hongliu, Vice President of Beijing Pulmongene Ltd.
Keynote Discussion: It's Time for Chinese Innovative Pharmaceutical Companies to Ride the Wind to the Sea
Moderator: Du Tao, Chairman of Shenzhen Evergreen Therapeutics
Discussants: He Ruyi, Chief Medical Officer of RemeGen Co., Ltd., Chief Scientist of SDIC Innovation, former Chief Scientist of CDE
Li Ning, CEO of Shanghai Junshi Bioscience
Zhao Xiaobin, Chairman of the Board, Haichang BioTech
Chen Shaoyu, Managing Partner, Arnold & Porter LLP
★International Pharmaceutical Innovation Industry Cooperation Forum★
Keynote Presentation 1: Joint Research and Prospects for New Drugs from Central Asian Specialty Natural Products
Rapporteur: Ajiaikbayr Isa, President of Xinjiang Medical University and Distinguished Researcher of Xinjiang Institute of Physical and Chemical Technology, Chinese Academy of Sciences
Keynote Presentation 2: Ambassadors/Counsellors of SCO countries in China introduce the development of their pharmaceutical industry and drug regulatory policies
Keynote Presentation 3: Introduction to Singapore's Biopharmaceutical Industry and Pharmacovigilance Policy
Rapporteur: Cai Zonglun, Deputy Director, Greater China, Economic Development Board, Singapore; Counsellor, Industry and Investment Division, Embassy of the Republic of Singapore, China
Keynote Presentation 4: Current Situation, Demand and Investment Environment of Pharmaceutical Industry in "One Belt One Road" Countries
Rapporteur: Bing Chen, Vice President, Head of Strategic Partnership and Business Development, AstraZeneca China
Topic Discussion: Challenges and Strategies for Innovative Medicines Going Overseas
Discussants: Yang Dajun, Chairman and CEO of ASCENTAGE PHARMA
Chen Li, Founder, CEO and Chief Scientific Officer of Hua Medicine Technology
★Innovative Medical Devices Forum★
Moderator: Wang Guangzhi, Long-appointed Professor, Department of Biomedical Engineering, School of Medicine, Tsinghua University
Keynote Report 1: Medical Device Clinical Trial Design and Quality Control
Reported by: State Drug Administration Medical Device Technical Review Center
Keynote Report 2: Innovation and Development in the Global Medical Device Industry
Rapporteur: Deng Jianmin, Senior Vice President and General Manager of Greater China, BDX Medical Global
Moderator: Wang Jingjing, Executive Director, Global Health Industry Innovation Center
Keynote Report 3: Development and Iteration of Innovative Medical Devices
Rapporteur: Wang Guangzhi, Long-appointed Professor, Department of Biomedical Engineering, School of Medicine, Tsinghua University
Keynote Report 4: Human Organ Chip and Precision Medicine
Rapporteur: Gu Zhongze, Dean, School of Biological Sciences and Medical Engineering, Southeast University
Topic Discussion: Opportunities and Innovative Directions for the Development of Innovative Medical Devices in China under the New Situation
Moderator: Li Ping, Vice President, Greater China, BDX Medical
Discussantss: Tian Yuan, Founding Partner of Yuanming Capital and Chairman of Mevion Medical Systems
Wang Yilong, Vice President of Tiantan Hospital, Capital Medical University
Gu Liping, Vice President of Med-X Research Institute, Shanghai Jiao Tong University, Professor of School of Biomedical Engineering and Institute of Medical Robotics
Wang Shaokang, Co-founder & General Manager of Infervision Medical Technology Co.
Yu Fang, Partner, Northern Light Venture Capital
★Clinical Research and Pharmaceutical Innovation Collaboration Forum★
Moderator: Cui Yimin, Chairman of the Special Committee on Drug Clinical Trials, China Pharmaceutical Innovation and Research Development Association, Director of the Institute of Clinical Pharmacology, Peking University
Policy Leadership - Overall Improvement of Clinical Research Capability
Moderator: Huang Hai, President of Fosun Kite Biotechnology Co.
Report 1: Clinical studies to accelerate the development of new technologies and new target drugs
Rapporteur: Song Yuqin, Vice President, Beijing Cancer Hospital
Report 2: International Multicenter Research and Globalization of Innovative Medicines
Rapporteur: Zhang Dan, Foreign Member of the Russian Academy of Engineering, Co-founder and Chief Strategy Officer of ClinChoice Medical Development Limited
Report 3 : Prospects for the construction and development of research-based hospitals
Rapporteur: Li Ning, Vice President, Cancer Hospital, Chinese Academy of Medical Sciences
Thematic discussion: To enhance the level of clinical research capability by focusing on patient needs
Moderator: Li Shuya, Director of GCP Center, Tiantan Hospital
Discussants: Zhu Chuowen, Director of Shanghai Clinical Research Center (President)
Li Peiying, Director of Clinical Research Center, Renji Hospital, Shanghai Jiaotong University
Practice Innovation - Promote the transformation of research results into practice
Moderator: Zhu Jun, President of Shanghai Henlius Biotech, Inc.
Report 4: Effectiveness and Reflections on the Construction of Clinical Science and Technology Parks in Public Hospitals
Rapporteur: Qin Huanlong, President, Shanghai Tenth People's Hospital
Report 5 : To be determined
Rapporteur: Miao Liyan, Vice President, The First Hospital of Suzhou University
Thematic discussion: To break the key blockage of the combination of industry, academia, research and medicine to accelerate the transformation of results
Moderator: Zhou Xu, Deputy General Manager, Shanghai Institute of Biological Products Co.
Discussants: Heads of GCP center in some hospitals
★Forum on Innovative Drug Basic Research and Results Transformation★
Moderator: Zhang Ao, Dean, School of Pharmacy, Shanghai Jiaotong University
Opening presentation: Small molecule drug research for anti-tumor immunotherapy
Rapporteur: Zhang Ao, Dean, School of Pharmacy, Shanghai Jiaotong University
Keynote Report 1: To be determined
Rapporteur: Chen Kaixian, Academician of the Chinese Academy of Sciences
Keynote Report 2: The significance of original innovation to the pharmaceutical industry
Rapporteur: Zhang Lianshan, Vice General Manager, Hengrui Pharmaceutical Group
Keynote 3: Basic Research Drives Innovative Drug Development
Rapporteur: Liu Junling, General Manager of Shanghai Xunshu Biotechnology Co.
Discussion Topic: Thinking about breaking the institutional and technical barriers of source innovation
Moderator: Zhang Ao, Dean, School of Pharmacy, Shanghai Jiao Tong University
Discussants: Li Jia, Director, Shanghai Institute of Pharmaceutical Sciences, Chinese Academy of Sciences
Zhou Bing, Researcher, Shanghai Institute of Pharmaceutical Sciences, Chinese Academy of Sciences
Wang Rong, Head of Lilly's China Innovation Collaboration Center
★Investment & M&A Forum★
Moderator: Zhang Li, Founding Managing Director of TT Capital
Keynote Report 1: To be determined
Rapporteur: Wang Xin, Asian Bioinnovation Center, Servier Pharmaceuticals, France
Presentation 2: Innovative Strategies for Lilly's External Partnerships
Rapporteur: Wang Rong, Head/ Vice President of China of Lilly China Innovation Collaboration Center
Discussion topic: Exploring the structural change trend of the investment and M&A sector in the pharmaceutical industry
Moderator: Zhang Li, Founding Managing Director of TT Capital
Discussantss: Zhou Zejian, Chief Financial Officer, Kelun-Biotech Biopharmaceutical Co.
Yi Lin, Partner of GL Capital
★Capital Market Innovation Service Forum★
Moderator: Xiao Hui, Partner, Ernst & Young Hua Ming LLP
Opening report: To be determined
Rapporteur: Zhang Xiaoxia, Vice President, Global Listing Services, HKEx
Keynote Report 1: Industry Status and Development Trend of Nucleic Acid Drugs
Rapporteur: Mao Hua, Head of Greater China, Frost & Sullivan
Keynote Report 2: To be determined
Rapporteur: Zhang Zhong, Head of Capital Markets Business, Zhonglu Law Firm
Keynote Report 3: To be determined
Rapporteur: Yang Shujuan, Partner-in-Charge of Ernst & Young Beijing, Partner-in-Charge of Government and Infrastructure Markets, Ernst & Young Greater China, Ernst & Young Hua Ming LLP (Special General Partner)
For more information, please check https://cbiic.phirda.com/
Registration: http://s.31url.cn/NaejvC8v